STOCK TITAN
  1. Home
  2. News
  3. NWBO

Northwest Biotherapeutics Inc - NWBO STOCK NEWS

Welcome to our dedicated news page for Northwest Biotherapeutics (Ticker: NWBO), a resource for investors and traders seeking the latest updates and insights on Northwest Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Northwest Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Northwest Biotherapeutics's position in the market.

News
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Rhea-AI Summary
Northwest Biotherapeutics appoints Mr. Pat Sarma to its Board of Directors, bringing extensive business and venture capital experience. Mr. Sarma, a longtime NWBio shareholder, will enhance the company's leadership with his background in technology and investing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
management
-
News
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Rhea-AI Summary
Northwest Biotherapeutics (NWBO) has completed the key development work for the Flaskworks manufacturing system and broadened its patent coverage. The system will play a vital role in scaling up manufacturing for DCVax-L products, reducing costs, and enabling widespread use as a frontline therapy. The company has completed intensive development work, including automating key steps in the manufacturing process and producing finished DCVax-L products. The tight adherence of dendritic cells was a significant challenge, but the company anticipates multiple benefits from implementing the Flaskworks system, such as lower manufacturing costs and increased efficiency. The next steps involve making GMP-grade units of the prototype Flaskworks machine and undertaking final qualification and validation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
none
-
News
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Rhea-AI Summary
Northwest Biotherapeutics (NWBO) announces the submission of a Marketing Authorization Application for DCVax-L for glioblastoma brain cancer, seeking approval for both newly diagnosed and recurrent patients. The application also requests to be considered under the MHRA's rapid 150-day review pathway. The company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM patients treated with DCVax-L. The treatment aims to address the extensive heterogeneity of GBM and overcome the immunosuppressive microenvironment around the tumor, with potential applicability for most types of solid tumors. The Company also had positive results in its Phase 1 trial of DCVax-Direct for inoperable solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
none
News
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Rhea-AI Summary
Northwest Biotherapeutics (NWBO) provided an update on the development of DCVax® personalized immune therapies for solid tumor cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
none
-
News
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
Rhea-AI Summary
Northwest Biotherapeutics provides update on progress towards submission of Marketing Authorization Application for DCVax-L treatment for glioblastoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.66%
Tags
none
-
News
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Rhea-AI Summary
Northwest Biotherapeutics announces addition of Dr. Linda Liau to Scientific Advisory Board
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
management
News
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
none
-
News
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
News
Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Stock NWBO logo
Northwest Biotherapeutics Inc

OTC:NWBO

NWBO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NWBO Stock Data

618.78M
1.11B
10.04%
0.25%
11.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bethesda

About NWBO

northwest biotherapeutics, inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. the company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. the company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. the company’s platform technology, dcvax®, uses a patient’s own dendritic cells, the starter engine of the immune system. the dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘